A new paper by a team of scientists from across the U.S. provides quantifiable data that can be used by national groups ...

AIxMed's experience in AI-based cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come ...

Lumea and AIxMed team up to bring AI driven urine cytology to Lumea's platform, targeting improved bladder cancer diagnostics. SANTA CLARA, Calif., May 30, 2025 /PRNewswire/ -- AIxMed, an ...

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) ...

Multigene panels for next-generation sequencing (NGS) are now US Food and Drug Administration (FDA)-approved in several tumor types. 1 In 2020 alone, 28 targeted therapies were approved by the FDA in ...

Total 497 GIST patients were involved in present study, with a median age of 60 years (range 23–90) and 55.9% was male. Stomach and small bowel were the most common sites of primary disease (59. ...

Gastrointestinal stromal tumors are among the first solid tumors for which cancer-(cell-)specific therapy became available. What is its pathogenesis, therapy strategies and drug resistance mechanisms?

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study presented at an ASCO meeting.

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set ...

WALTHAM, Mass., May 31, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...